IL-17 suppresses the therapeutic activity of cancer vaccines through the inhibition of CD8+ T-cell responses

Autor: Gilles Dadaglio, Catherine Fayolle, Marine Oberkampf, Alexandre Tang, Francesc Rudilla, Isabelle Couillin, Eirik A. Torheim, Pierre Rosenbaum, Claude Leclerc

Publikováno v: OncoImmunology, Vol 9, Iss 1 (2020)

Antitumor immunity is mediated by Th1 CD4+ and CD8+ T lymphocytes, which induce tumor-specific cytolysis, whereas Th17 CD4+ T cells have been described to promote tumor growth. Here, we explored the influence of IL-17 on the ability of therapeutic va

Externí odkaz: https://doaj.org/article/5233de5bf6bf40c49d8d32de56bb46e2

Supplementary Figures S1-S10 from Rapamycin Impairs Antitumor CD8+ T-cell Responses and Vaccine-Induced Tumor Eradication

Autor: Claude Leclerc, Daniel Ladant, Alexandre Tang, Marine Oberkampf, Belinda Desrues, Catherine Fayolle, Nada Chaoul

Supplementary Figure S1. T-cell gating strategy in the spleen, lymph nodes and tumors. Supplementary Figure S2. Rapamycin treatments inhibit the lymphocyte recruitment to the spleen and abrogate CyaA-E7's effect. Supplementary Figure S3. MDSC gating

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ba72dfc0d49524b978e73487ef23d2b
https://doi.org/10.1158/0008-5472.22405073.v1

Abstract 2960: The novel trifunctional anti-BCMA NK cell engager SAR’514 has potent in-vitro, in-vivo and ex-vivo anti-myeloma effect through dual NK cell engagement

Autor: Alexandre Tang, Laurent Gauthier, Jochen Beninga, Benjamin Rossi, Nicolas Gourdin, Audrey Blanchard-Alvarez, Céline Amara, Jacqueline Courta, Alexandra Basset, Dorothée Bourges, Alexandre Desjonqueres, Emmanuelle Menoret, Catherine Pellat-Deceunynck, Philippe Moreau, Yannis Morel, Marielle Chiron, Eric Vivier, Angela Virone-Oddos

Publikováno v: Cancer Research. 83:2960-2960

Multiple Myeloma (MM) is the second most prevalent hematopoietic malignancy, representing 10% of total blood cancers. Despite the emergence of new therapies, it is still an incurable disease. Safe, potent and innovative approaches with long lasting b

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a037ddccbedaf8134afaf91f82c7a2f7
https://doi.org/10.1158/1538-7445.am2023-2960

IL-17 suppresses the therapeutic activity of cancer vaccines through the inhibition of CD8 + T-cell responses

Autor: Marine Oberkampf, Alexandre Tang, Eirik A Torheim, Pierre Rosenbaum, Gilles Dadaglio, Claude Leclerc, Francesc Rudilla, Catherine Fayolle, Isabelle Couillin

Publikováno v: OncoImmunology
OncoImmunology, 2020, 9 (1), pp.1758606. ⟨10.1080/2162402X.2020.1758606⟩
OncoImmunology, Vol 9, Iss 1 (2020)
Oncoimmunology
article-version (VoR) Version of Record
OncoImmunology, Taylor & Francis, 2020, 9 (1), pp.1758606. ⟨10.1080/2162402X.2020.1758606⟩

International audience; Antitumor immunity is mediated by Th1 CD4+ and CD8+ T lymphocytes, which induce tumor-specific cytolysis, whereas Th17 CD4+ T cells have been described to promote tumor growth. Here, we explored the influence of IL-17 on the a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94dc82471f49677a69f2e55ba9943e36
https://hal.science/hal-03100073

Abstract 2266: SAR442085, a next generation anti-CD38 antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC) against multiple myeloma

Autor: Céline Nicolazzi, Sukhvinder Sidhu, Marielle Chiron, Angela Virone-Oddos, Isabelle Arnould, Ludovic Martinet, Alexandre Tang, Nadege Carrie-Constantin, Sahar Kassem, Béré K. Diallo, Alain Fournier, Nizar El-Murr, Hervé Avet-Loiseau

Publikováno v: Cancer Research. 80:2266-2266

CD38 is a cell surface glycoprotein highly expressed in multiple myeloma (MM) cells making it an attractive target for antibody–based therapy. Anti–CD38 treatment represents a major breakthrough in the treatment of relapsing and refractory multip

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9139cbf3074ac2280739f199933c3e53
https://doi.org/10.1158/1538-7445.am2020-2266